NeuroEM

NeuroEM operates at the intersection of medical devices, neurotechnology, and digital therapeutics, with a narrower focus than general cognitive-health platforms. Its lead product, the MemorEM wearable, delivers Transcranial Electromagnetic Treatment using Radio Frequencies (TEMT-RF) and is intended for non-invasive, drug-free, in-home use. That places the company conceptually alongside non-invasive neuromodulation developers such as Neuronetics and BrainsWay, although NeuroEM’s stated Alzheimer’s and cognitive-decline focus differs from the established indications associated with those companies. It also occupies a distinct position relative to pharmaceutical Alzheimer’s programs because its proposed mechanism is device-based rather than drug-based. The differentiation is meaningful but not yet validated by disclosed commercial scale: NeuroEM has raised $1.33 million in its Series A, has a reported team size of roughly 11–50 employees, and remains private. Public information does not establish a definitive competitor ranking, comparative clinical efficacy, reimbursement position, or FDA clearance status. Its market position is therefore best characterized as an early-stage, clinically oriented device challenger pursuing a specialized neurodegenerative-disease use case.

NeuroEM’s trajectory shows a long development period followed by a recent shift toward clinical and commercial execution. The company was founded on Jan 31, 2013, and its website describes more than a decade of research behind the MemorEM device and TEMT-RF approach. A pre-seed round dated Jan 1, 2015 indicates early external financing, although the amount is not publicly specified. The major disclosed inflection point came on Jun 13, 2025, when NeuroEM raised $1.33 million in Series A funding from Bluelake. One month later, on Jul 10, 2025, CareONE Concierge began accepting candidates for an Alzheimer’s device study, suggesting that the financing was being paired with patient-recruitment activity. The appointment of Dr. W. Scott Burgin as Chief Medical Officer on Jan 30, 2026 added dedicated clinical leadership and may support trial, R&D, and regulatory work. The reported employee band of 11–50 suggests a relatively lean organization. There is no disclosed hiring plan, revenue data, approval milestone, or employee-growth series, so the evidence supports measured progression rather than a demonstrated scale-up.